Clinical and pathological disappearance of peritoneal dissemination in a patient with advanced gastric cancer receiving chemotherapy with S-1 and low-dose cisplatin

被引:4
|
作者
Akatsu Y. [1 ]
Saikawa Y. [1 ]
Kubota T. [1 ]
Yoshida M. [1 ]
Furukawa T. [1 ]
Otani Y. [1 ]
Kumai K. [2 ]
Kitajima M. [1 ]
机构
[1] Department of Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582
[2] Ctr. for Diagn./Therapeut. Endoscopy, Keio University School of Medicine, Tokyo
关键词
Cisplatin; Gastric cancer; Peritoneal dissemination; S-1;
D O I
10.1007/s10120-004-0281-8
中图分类号
学科分类号
摘要
A 54-year-old woman with severe abdominal distention suffered from massive ascites. Cytological examination revealed adenocareinoma cells, leading to a diagnosis of peritonitis carcinomatosa. Gastrointestinal fiberseopy (GIF) resulted in a histological diagnosis of type 4 advanced gastric cancer with signet-ring cell carcinoma. The clinical diagnosis was confirmed to be cT3(SE)cN1cM0cH0cP1, cStage IV gastric cancer, type 4, according to the Japanese classification of gastric carcinoma. The patient was treated with S-1 and low-dose cisplatin (CDDP) in order to alleviate the critical state of the disease. After the third cycle of the regimen, the clinical response of P1 was classified as a partial response (PR) according to the World Health Organization (WHO) criteria. The patient's appetite loss and abdominal discomfort were markedly alleviated. The patient experienced grade 2 leukocytopenia throughout the regimen. Surgery was performed. Ascites and peritoneal disseminated lesions were not observed, and cytological examination of the peritoneal washes was negative. Total gastrectomy with D1 lymph node dissection was performed, and the surgical diagnosis was sT3(SE)sN0sM0sH0sP0; sStage II Microscopically, viable cancer cells were found to be scattered throughout the subserosal-serosal layers in the resected stomach. All of the samples from lesions that were potentially cancers involving peritoneal dissemination were diagnosed as fibrous scar tissues without any viable cancer cells. The patient is alive without recurrence at 10 months after surgery and 14 months after the initial chemotherapy. Thus, systemic chemotherapy with S-1/low-dose CDDP achieved desirable control of peritoneal disseminated cells, as assessed microscopically, suggesting that the regimen may be an effective strategy for the treatment of advanced gastric cancer with peritonitis carcinomatosa.
引用
收藏
页码:128 / 133
页数:5
相关论文
共 50 条
  • [31] Feasibility Study of S-1 and Intraperitoneal Docetaxel Combination Chemotherapy for Gastric Cancer with Peritoneal Dissemination
    Fujiwara, Yoshiyuki
    Nishida, Toshiro
    Takiguchi, Shuji
    Nakajima, Kiyokazu
    Miyata, Hiroshi
    Yamasaki, Makoto
    Yamamoto, Kazuyoshi
    Moon, Jeong-Ho
    Mori, Masaki
    Doki, Yuichiro
    ANTICANCER RESEARCH, 2010, 30 (04) : 1335 - 1339
  • [32] Feasibility and Efficacy of Combination Chemotherapy with S-1 and Fractional Cisplatin for Advanced Gastric Cancer
    Takahashi, Tsunehiro
    Saikawa, Yoshiro
    Takaishi, Hiromasa
    Takeuchi, Hiroya
    Wada, Norihito
    Oyama, Takashi
    Nakamura, Rieko
    Kitagawa, Yuko
    ANTICANCER RESEARCH, 2010, 30 (09) : 3759 - 3762
  • [33] A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer
    Shunsuke Okazaki
    Takako E. Nakajima
    Jun Hashimoto
    Seiichiro Yamamoto
    Daisuke Takahari
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Kenji Tamura
    Gastric Cancer, 2013, 16 : 41 - 47
  • [34] Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination
    Kunitoshi Shigeyasu
    Shunsuke Kagawa
    Futoshi Uno
    Masahiko Nishizaki
    Hiroyuki Kishimoto
    Akira Gochi
    Toshikazu Kimura
    Takaomi Takahata
    Yasuyuki Nonaka
    Motoki Ninomiya
    Toshiyoshi Fujiwara
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 937 - 943
  • [35] Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination
    Shigeyasu, Kunitoshi
    Kagawa, Shunsuke
    Uno, Futoshi
    Nishizaki, Masahiko
    Kishimoto, Hiroyuki
    Gochi, Akira
    Kimura, Toshikazu
    Takahata, Takaomi
    Nonaka, Yasuyuki
    Ninomiya, Motoki
    Fujiwara, Toshiyoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 937 - 943
  • [36] Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer
    Ina, Shinomi
    Tani, Masaji
    Kawai, Manabu
    Hirono, Seiko
    Miyazawa, Motoki
    Nishioka, Ryohei
    Fujita, Yoichi
    Yamaue, Hiroki
    ANTICANCER RESEARCH, 2008, 28 (4C) : 2373 - 2377
  • [37] Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study
    Kunisaki, Chikara
    Ono, Hidetaka A.
    Hasegawa, Shinichi
    Oshima, Takashi
    Fujii, Shoichi
    Tokuhisa, Motohiko
    Izumisawa, Yusuke
    Takagawa, Ryo
    Kimura, Jun
    Kosaka, Takashi
    Makino, Hirochika
    Akiyama, Hirotoshi
    Endo, Itaru
    JOURNAL OF CHEMOTHERAPY, 2012, 24 (06) : 364 - 372
  • [38] Adjuvant S-1 Chemotherapy for Gastric Cancer and Peritoneal Wash
    Seiji Ito
    World Journal of Surgery, 2011, 35 : 470 - 471
  • [39] S-1 adjuvant chemotherapy for advanced gastric cancer
    David Kelsen
    Nature Clinical Practice Oncology, 2008, 5 : 370 - 371
  • [40] S-1 adjuvant chemotherapy for advanced gastric cancer
    Kelsen, David
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 370 - 371